175 related articles for article (PubMed ID: 38340704)
1. Gemcitabine with cisplatin and nivolumab: Redefining standard of care for first-line metastatic urothelial carcinoma?
Mathew Thomas V; Grivas P; Agarwal N
Med; 2024 Feb; 5(2):109-111. PubMed ID: 38340704
[TBL] [Abstract][Full Text] [Related]
2. Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.
Powles T; Valderrama BP; Gupta S; Bedke J; Kikuchi E; Hoffman-Censits J; Iyer G; Vulsteke C; Park SH; Shin SJ; Castellano D; Fornarini G; Li JR; Gümüş M; Mar N; Loriot Y; Fléchon A; Duran I; Drakaki A; Narayanan S; Yu X; Gorla S; Homet Moreno B; van der Heijden MS;
N Engl J Med; 2024 Mar; 390(10):875-888. PubMed ID: 38446675
[TBL] [Abstract][Full Text] [Related]
3. Nivolumab plus Gemcitabine-Cisplatin in Advanced Urothelial Carcinoma.
van der Heijden MS; Sonpavde G; Powles T; Necchi A; Burotto M; Schenker M; Sade JP; Bamias A; Beuzeboc P; Bedke J; Oldenburg J; Chatta G; Ürün Y; Ye D; He Z; Valderrama BP; Ku JH; Tomita Y; Filian J; Wang L; Purcea D; Patel MY; Nasroulah F; Galsky MD;
N Engl J Med; 2023 Nov; 389(19):1778-1789. PubMed ID: 37870949
[TBL] [Abstract][Full Text] [Related]
4. Enfortumab vedotin and pembrolizumab as new first-line standard for metastatic urothelial cancer.
Zhu X; Koshkin VS
Med; 2024 Feb; 5(2):106-108. PubMed ID: 38128535
[TBL] [Abstract][Full Text] [Related]
5. Systemic treatment of advanced and metastatic urothelial cancer: The landscape in Australia.
Gurney H; Clay TD; Oliveira N; Wong S; Tran B; Harris C
Asia Pac J Clin Oncol; 2023 Dec; 19(6):585-595. PubMed ID: 37727139
[TBL] [Abstract][Full Text] [Related]
6. Gemcitabine for unresectable, locally advanced or metastatic bladder cancer.
Shelley M; Cleves A; Wilt TJ; Mason M
Cochrane Database Syst Rev; 2011 Apr; (4):CD008976. PubMed ID: 21491413
[TBL] [Abstract][Full Text] [Related]
7. The Overall Survival Benefit in EV-302: Is Enfortumab Vedotin plus Pembrolizumab the New Frontline Standard of Care for Metastatic Urothelial Carcinoma?
Benjamin DJ; Rezazadeh Kalebasty A; Prasad V
Eur Urol Oncol; 2024 Jun; 7(3):313-315. PubMed ID: 38485615
[TBL] [Abstract][Full Text] [Related]
8. Open-label randomized multi-center phase 2 study: gemcitabine cisplatin plus avelumab or gemcitabine cisplatin as first-line treatment of patients with locally advanced or metastatic urothelial bladder carcinoma: GCisAve.
Gross-Goupil M; Domblides C; Lefort F; Ravaud A
Bull Cancer; 2020 Jun; 107(5S):eS1-eS7. PubMed ID: 32620210
[TBL] [Abstract][Full Text] [Related]
9. [Second-line treatment of metastatic urothelial carcinoma : Update immuno-oncology].
Zschäbitz S; Niegisch G
Urologe A; 2020 Jul; 59(7):804-809. PubMed ID: 32472222
[TBL] [Abstract][Full Text] [Related]
10. [First line therapy for locally advanced or metastatic urothelial cancer : A randomized double blind phase III multicenter study on adjuvant nivolumab therapy versus placebo in patients with invasive high-risk urothelial cancer (CheckMate 274)-AB 58/17 of the AUO].
Rexer H; Ohlmann CH; Gschwend J;
Urologe A; 2017 Oct; 56(10):1331-1332. PubMed ID: 28779222
[No Abstract] [Full Text] [Related]
11. First-line Management of Metastatic Urothelial Cancer: Current and Future Perspectives After the EV-302 and CheckMate-901 Studies.
Fenor de la Maza MD; Villacampa G; Miñana B; Barbas Bernardos G; Andrés G; González-Padilla DA; Ramón de Fata F; Sanz J; Cambeiro M; Aristu J; Gúrpide A; Villacampa F; Gracia JLP
Clin Genitourin Cancer; 2024 Apr; 22(2):330-335. PubMed ID: 38172023
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of Pembrolizumab for Patients with Advanced, Unresectable, or Metastatic Urothelial Cancer Ineligible for Cisplatin-based Therapy.
Patterson K; Prabhu V; Xu R; Li H; Meng Y; Zarabi N; Zhong Y; Batteson R; Pellissier J; Keefe S; Grivas P; de Wit R
Eur Urol Oncol; 2019 Sep; 2(5):565-571. PubMed ID: 31412011
[TBL] [Abstract][Full Text] [Related]
13. Immune checkpoint inhibitors for urothelial carcinoma.
Kim HS; Seo HK
Investig Clin Urol; 2018 Sep; 59(5):285-296. PubMed ID: 30182073
[TBL] [Abstract][Full Text] [Related]
14. Successful treatment of metastatic urothelial carcinoma arising in a transplanted renal allograft with paclitaxel, cisplatin, and gemcitabine combination therapy: a case report.
Kojima Y; Takahi Y; Ichimaru N; Okumi M; Takahara S; Nonomura N
BMC Res Notes; 2015 Feb; 8():25. PubMed ID: 25648269
[TBL] [Abstract][Full Text] [Related]
15. Gemcitabine Plus Cisplatin Split
Izumi K; Iwamoto H; Yaegashi H; Shigehara K; Nohara T; Kadono Y; Mizokami A
In Vivo; 2019; 33(1):167-172. PubMed ID: 30587618
[TBL] [Abstract][Full Text] [Related]
16. Larotaxel with Cisplatin in the first-line treatment of locally advanced/metastatic urothelial tract or bladder cancer: a randomized, active-controlled, phase III trial (CILAB).
Sternberg CN; Skoneczna IA; Castellano D; Theodore C; Blais N; Voog E; Bellmunt J; Peters F; Le-Guennec S; Cerbone L; Risse ML; Machiels JP
Oncology; 2013; 85(4):208-15. PubMed ID: 24080920
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of Pembrolizumab versus Carboplatin-based Chemotherapy as First-line Treatment of PD-L1-positive Locally Advanced or Metastatic Urothelial Carcinoma Ineligible for Cisplatin-based Therapy in the United States.
Hale O; Patterson K; Lai Y; Meng Y; Li H; Godwin JL; Homet Moreno B; Mamtani R
Clin Genitourin Cancer; 2021 Feb; 19(1):e17-e30. PubMed ID: 32826180
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant Chemotherapy with Gemcitabine plus Cisplatin in Patients with Locally Advanced Bladder Cancer.
Niedersüss-Beke D; Puntus T; Kunit T; Grünberger B; Lamche M; Loidl W; Böhm R; Kraischits N; Kudlacek S; Schramek P; Meran JG
Oncology; 2017; 93(1):36-42. PubMed ID: 28399521
[TBL] [Abstract][Full Text] [Related]
19. Gemcitabine, Cisplatin, and sunitinib for metastatic urothelial carcinoma and as preoperative therapy for muscle-invasive bladder cancer.
Galsky MD; Hahn NM; Powles T; Hellerstedt BA; Lerner SP; Gardner TA; Yu M; O'Rourke M; Vogelzang NJ; Kocs D; McKenney SA; Melnyk AM; Hutson TE; Rauch M; Wang Y; Asmar L; Sonpavde G
Clin Genitourin Cancer; 2013 Jun; 11(2):175-81. PubMed ID: 23228446
[TBL] [Abstract][Full Text] [Related]
20. FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Cisplatin-Ineligible Locally Advanced or Metastatic Urothelial Carcinoma.
Maguire WF; Lee D; Weinstock C; Gao X; Bulik CC; Agrawal S; Chang E; Hamed SS; Bloomquist EW; Tang S; Pazdur R; Kluetz PG; Amiri-Kordestani L; Suzman DL
Clin Cancer Res; 2024 May; 30(10):2011-2016. PubMed ID: 38441576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
